A phase I non-randomized, open label, adaptive, parallel group, human positron emission tomography (PET) study to assess the occupancy of brain γ1 and γ2 containing GABAA receptors of RO7308480 using [11C]RO7285378 and [11C]flumazenil following single oral doses in healthy participants
Latest Information Update: 02 Jul 2024
At a glance
- Drugs Flumazenil (Primary) ; RO 7308480 (Primary)
- Indications Anxiety disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 04 Dec 2023 Status changed from recruiting to completed.
- 17 Feb 2023 Status changed from not yet recruiting to recruiting.
- 13 Feb 2023 New trial record